Abstract
Myasthenia gravis is an autoimmune disorder of the neuromuscular junction caused by circulating antibodies specific for the post-synaptic receptor.It results in neuromuscular transmission disorders.After optimal treatment with standard drugs, most myasthenia gravis patients can achieve a good life quality.Part of patients cannot get stable clinical remission or minimal manifestation with standard therapy.Rituximab is a chimeric mouse/human antibody specific for the CD20 B-cell surface antigen.Studies have showed that rituximab is effective in the refractory myasthenia gravis.This review mainly discusses about the advances of rituximab in the treatment of refractory myasthenia gravis. Key words: Refractory myasthenia gravis; Rituximab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
